SCHEMBL2360243

SCHEMBL2360243

CC1(C)CC(O)CC(C)(C(=O)Nc2ccc(Cl)c(Cl)c2)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 2/20 0.45
EPHX2 P34913 2/20 0.45
NPC1 O15118 5/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
RAB9A P51151 4/20 0.44
LMNA P02545 2/20 0.44
CYP3A4 P08684 1/20 0.43
APEX1 P27695 1/20 0.43
CA2 P00918 1/20 0.42
CA4 P22748 1/20 0.42
CA5A P35218 1/20 0.42
CA9 Q16790 1/20 0.42
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
PKM P14618 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
CHRM1 P11229 1/20 0.41
SLC6A2 P23975 1/20 0.41
PDE4A P27815 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12351017 0.89 IDO1 (0.40) MAPT
SCHEMBL12351016 0.86 KDR (0.52) EPHX2MEN1KMT2ALMNACA2
SCHEMBL2359845 0.84 MEN1 (0.47) EPHX1EPHX2NPC1MEN1KMT2A
SCHEMBL2360156 0.83 KMT2A (0.40) MEN1KMT2ARAB9AMAPTPOLB
SCHEMBL2358740 0.80 EPHX2 (0.43) EPHX1EPHX2NPC1MEN1KMT2A
SCHEMBL2359771 0.80 LMNA (0.44) EPHX1EPHX2NPC1MEN1KMT2A
SCHEMBL2359355 0.79 FADS1 (0.43) MEN1KMT2ALMNACA2NLRP3
SCHEMBL10521499 0.79 EPHX1 (0.58) EPHX1EPHX2NPC1MEN1KMT2A
SCHEMBL12350998 0.78 GRM4 (0.43) EPHX2MEN1KMT2ARAB9A
SCHEMBL2360096 0.77 EPHX2 (0.34) EPHX2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011095576-A1 COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA F. HOFFMANN-LA ROCHE AG (CH) 2011-08-11 WO disclosed
WO-2011094953-A1 COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA F. HOFFMANN-LA ROCHE AG (CH) 2011-08-11 WO disclosed
WO-2011095576-A1 COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA F. HOFFMANN-LA ROCHE AG (CH) 2011-08-11 WO disclosed
US-20110195979-A1 COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA F. HOFFMANN-LA ROCHE AG (CH) 2011-08-11 US disclosed
US-20110195979-A1 COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA F. HOFFMANN-LA ROCHE AG (CH) 2011-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195979-A1 COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA NAT1, NHERF1, ADORA1 EPHX1 2876/4885EPHX2 4462/4885NPC1 356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.